The metabolites are mainly excreted via the kidney.The activation and deactivation pathway is analogous to the one of tafluprost (at least up to the tetranor-metabolite); compare Tafluprost#Pharmacokinetics. Chemistry
Stability
Latanoprost exhibits thermal and solar instability. The concentration of latanoprost stored at 50 °C will decrease by 10% every 8.25 days. When stored at 70 °C the concentration will decrease by 10% every 1.32 days. Ultraviolet light, for example in sunlight, causes rapid degradation of latanoprost. Society and culture
The brand Xalatan is manufactured by Pfizer. Cosmetic use
Lengthening and thickening of the eyelashes (used, like bimatoprost, in the cosmetic industry as eyelash growth enhancers). There is one small study that found benefit in androgenic alopecia. References
External links
"Latanoprost". Drug Information Portal. U.S. National Library of Medicine.
It is not for long term definitive treatment/cure, only as an adjunct (surgery is the aim for cure in most causes of Cushings syndrome). Metyrapone hence acts by inhibiting adrenal steroidogenesis. One side effect is hirsutism (in women) because of the excess androgen precursors created. The other commonly used agent for medical treatment of Cushings is ketoconazole (an anti-fungal agent). This does not exhibit the side effect of hirsutism. Pharmacology
Pharmacodynamics
Metyrapone blocks cortisol steroidogenesis by acting as a reversible inhibitor of 11β-hydroxylase. This stimulates adrenocorticotropic hormone (ACTH) secretion, which in turn increases plasma 11-deoxycortisol levels. Chemistry
Analogues of metyrapone include aminoglutethimide, amphenone B, and mitotane. Research
Metyrapone has been found in early human trials to reduce recollection of emotional memories in normal volunteers. The volunteers showed significant impairment in ability to retrieve memories with negative emotional content while not impairing memories with neutral content. This has significant implication in the study of the process of emotional healing in post traumatic stress disorder.Due to the permissive action of cortisol on glucagon, partial blockade of cortisol may reduce
the effects of circulating glucagon in chronically increasing blood glucose in metabolic syndrome (syndrome X) and type 2 diabetes. See also
ACTH stimulation test


== References ==